Search

Displaying results 901 - 910 of 7058 in total
  1. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers. … RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.

  2. Drug

    Dirlotapide

    go.drugbank.com/drugs/DB11399
    InvestigationalVet approved

    Dirlotapide is a drug employed in the treatment of obesity in dogs. It is marketed by Pfizer and Zoetis under the brand name, _Slentrol_, and is not intended for human use.

  3. Drug

    Heterotheca inuloides flower

    go.drugbank.com/drugs/DB14331
    Approved

    Heterotheca inuloides flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Arnica De LA Abuela
  4. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118] … [L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7,

  5. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    It is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn. … It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes.

    Synonyms: 4-OH-A
  6. Drug

    Alprostadil

    go.drugbank.com/drugs/DB00770
    ApprovedInvestigational

    This drug causes vasodilation by directly affecting vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. … Alprostadil is a chemically-identical synthetic form of prostaglandin E1 (PGE1), a potent vasodilator produced endogenously.

    International brands: Caverject DC
  7. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.

  8. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates. … It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.

  9. Drug

    Bictegravir

    go.drugbank.com/drugs/DB11799
    ApprovedInvestigational

    It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677] … Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection.

  10. Drug

    Ocriplasmin

    go.drugbank.com/drugs/DB08888
    ApprovedWithdrawn

    Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.